Kybella®

WHAT IS KYBELLA® TREATMENT FOR DOUBLE CHIN?

Kybella Margaret Sommerville, M.D., F.A.A.D.Kybella® is the first and only FDA- approved injectable treatment used to improve the appearance of moderate to severe fatty tissue below the chin, also called “double chin”. The active ingredient in moderate to severe fatty tissue below the chin, also called “double chin”. The active ingredient in Kybella® is deoxycholic acid, a naturally occurring molecule in the body that aids in the breakdown of dietary lipids. When injected into the fat beneath your chin, Kybella®destroys fat cells.

Kybella® is deoxycholic acid, a naturally occurring molecule in the body that aids in the breakdown of dietary lipids. When injected into the fat beneath your chin, Kybella®destroys fat cells.
As part of the clinical development program, Kybella® has been evaluated in more than 20 clinical studies. Featured on the Today Show, in the New York Times®, Allure® and Elle® magazines, Kybella® has been awarded 2015 Allure® Best of Beauty Breakthrough Award.

HOW MANY TREATMENTS WILL I NEED?

Most patients require only 2 to 3 treatment sessions spaced 6 to 8 weeks apart, however up to 6 treatments may be administered, if needed.

HOW IS KYBELLA ADMINISTERED?

Kybella® injection is performed during an office visit and the treatment takes 15 to 20 minutes. Most patients resume their normal activities after the injections are performed despite the swelling that is likely to occur at the injection sites. Ice or cold packs can be applied to the treatment area immediately after the injections.

WHAT ARE THE MOST COMMON SIDE EFFECTS?

The most common side effects include swelling, bruising, pain, numbness, redness and areas of hardness. Please call our office at 301.656.7546 to discuss possible contraindications and other implications of treatment.

Before After
Before After

WHAT ARE THE MOST COMMON SIDE EFFECTS?

The most common side effects include swelling, bruising, pain, numbness, redness and areas of hardness. Please call our office at 301.656.7546 to discuss possible contraindications and other implications of treatment.